TVTX
Travere Therapeutics Inc
52.00$
-2.6%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 82.4% | 78.2% | 72.5% | 67.0% | 64.4% | 70.1% | 68.2% | 68.4% | 68.9% | 72.3% | 70.7% | 77.0% | |
| 17.3% | 7.4% | 6.5% | 5.9% | 7.2% | 9.9% | 11.3% | 13.5% | 20.6% | 15.4% | 14.1% | 14.7% | |
| 76.2% | 71.9% | 66.5% | 59.0% | 55.0% | 62.4% | 58.7% | 57.5% | 47.3% | 53.3% | 47.7% | 61.2% | |
| 1.7% | 2.7% | 3.4% | 4.4% | 5.0% | 4.6% | 6.3% | 7.0% | 15.4% | 13.5% | 15.7% | 10.1% | |
| 2.5% | 1.2% | 0.7% | 1.1% | 1.3% | 1.0% | 0.7% | 0.7% | 1.0% | 1.0% | 1.1% | 1.0% | |
| 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | – | |
| 12.7% | 13.1% | 15.1% | 18.9% | 20.5% | 17.4% | 18.8% | 18.9% | 20.2% | 18.7% | 19.7% | 16.5% | |
| 66.4% | 74.5% | 88.8% | 97.3% | 106.0% | 90.1% | 94.0% | 94.1% | 86.3% | 81.0% | 82.2% | 96.9% | |
| 16.7% | 22.6% | 26.1% | 22.0% | 37.7% | 33.8% | 33.2% | 34.1% | 25.1% | 26.4% | 22.6% | 19.0% | |
| 0.6% | 0.6% | 0.8% | 0.9% | 14.6% | 12.5% | 13.5% | 13.4% | 1.1% | 1.0% | 1.1% | 0.8% | |
| 3.0% | 5.3% | 2.5% | 4.7% | 4.6% | 4.0% | 2.8% | 3.4% | 3.4% | 4.1% | 2.3% | 0.9% | |
| 45.2% | 47.8% | 56.9% | 68.6% | 61.4% | 52.2% | 56.6% | 56.0% | 57.8% | 51.5% | 56.2% | 75.4% | |
| 33.6% | 25.5% | 11.2% | 2.7% | -6.0% | 9.9% | 6.0% | 5.9% | 13.7% | 19.0% | 17.8% | 3.1% | |
| -124.3% | -142.7% | -190.1% | -241.7% | -275.0% | -243.6% | -271.2% | -270.3% | -273.9% | -243.3% | -271.9% | -193.2% | |
| 9.2% | 9.7% | 11.6% | 14.1% | 15.4% | 14.0% | 16.1% | 16.0% | 19.1% | 14.9% | 16.5% | 11.7% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.